Hypertension research : official journal of the Japanese Society of Hypertension · 2023
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Рандомизированное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kohagura Kentaro, Kojima Sunao, Uchiyama Kazuaki, Yokota Naoto, Tokutake Eiichi, Wakasa Yutaka, Hiramitsu Shinya, Waki Masako, Jinnouchi Hideaki, Kakuda Hirokazu, Hayashi Takahiro, Kawai Naoki, Sugawara Masahiro, Mori Hisao, Tsujita Kenichi, Matsui Kunihiko, Hisatome Ichiro, Ohya Yusuke, Kimura Kazuo, Saito Yoshihiko, Ogawa Hisao, Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators
Аннотация
Effect of urate-lowering on renal outcomes in patients at high-risk for cardiovascular disease with hyperuricemia without gout is not known. We conducted a post hoc analysis of a randomized trial (Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy [FREED]). The FREED trial enrolled 1070 asymptomatic, hyperuricemic elderly patients with at least one risk factor for cardiovascular disease, divided into febuxostat (n = 537) and non-febuxostat (n = 533) groups. We compared the effect of these treatments on renal outcomes including 40% decline in estimated glomerular filtration rate, new onset of microalbuminuria and development or worsening macroalbuminuria. The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24-0.82; P = 0.0098). However, the risks for other outcomes were comparable. In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of development or worsening of macroalbuminuria.